# Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

> **NCT07210554** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Chengdu Kangnuoxing Biopharma,Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Bullous Pemphigoid (BP)

## Interventions

- **BIOLOGICAL:** Stapokibart injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07210554
- **Lead sponsor:** Chengdu Kangnuoxing Biopharma,Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-11
- **Primary completion:** 2028-03-27
- **Final completion:** 2028-05-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07210554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07210554, "Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07210554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*